Innogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules

Bulletin Express03-23

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her roles as Joint Company Secretary, Hong Kong Agent for Service of Process and Authorised Representative due to personal career plans.

Industry veteran Mak Po Man Cherie, currently Vice President of SWCS Corporate Services Group (Hong Kong) Limited, will assume the three vacated positions on the same date. Mak brings more than 20 years of audit, accounting, corporate finance, compliance and corporate secretarial experience, and holds professional memberships with The Hong Kong Chartered Governance Institute, The Chartered Governance Institute, the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants.

Yang Dongyan, appointed Joint Company Secretary on 6 February 2026, will remain in her position and continue to serve as Innogen Pharmaceutical’s legal director.

The Stock Exchange of Hong Kong granted a new waiver allowing Yang to continue serving as Joint Company Secretary without meeting the full experience requirements under Listing Rules 3.28 and 8.17. The waiver is valid until 5 February 2029, provided Yang is assisted by Mak and no material Listing Rules breaches occur. Before the waiver expires, Innogen Pharmaceutical must demonstrate that Yang has gained sufficient experience to discharge company-secretary duties independently.

The board expressed appreciation for Sze’s contributions and welcomed Mak to her new roles.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180017707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180017707","market":"hk","top_or_hot":-1,"title":"Innogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her roles as Joint Company Secretary, Hong Kong Agent for Service of Process and Authorised Representative due to personal career plans.</p>\n<p>Industry veteran Mak Po Man Cherie, currently Vice President of SWCS Corporate Services Group (Hong Kong) Limited, will assume the three vacated positions on the same date. Mak brings more than 20 years of audit, accounting, corporate finance, compliance and corporate secretarial experience, and holds professional memberships with The Hong Kong Chartered Governance Institute, The Chartered Governance Institute, the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants.</p>\n<p>Yang Dongyan, appointed Joint Company Secretary on 6 February 2026, will remain in her position and continue to serve as Innogen Pharmaceutical’s legal director.</p>\n<p>The Stock Exchange of Hong Kong granted a new waiver allowing Yang to continue serving as Joint Company Secretary without meeting the full experience requirements under Listing Rules 3.28 and 8.17. The waiver is valid until 5 February 2029, provided Yang is assisted by Mak and no material Listing Rules breaches occur. Before the waiver expires, Innogen Pharmaceutical must demonstrate that Yang has gained sufficient experience to discharge company-secretary duties independently.</p>\n<p>The board expressed appreciation for Sze’s contributions and welcomed Mak to her new roles.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-23 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her roles as Joint Company Secretary, Hong Kong Agent for Service of Process and Authorised Representative due to personal career plans.</p>\n<p>Industry veteran Mak Po Man Cherie, currently Vice President of SWCS Corporate Services Group (Hong Kong) Limited, will assume the three vacated positions on the same date. Mak brings more than 20 years of audit, accounting, corporate finance, compliance and corporate secretarial experience, and holds professional memberships with The Hong Kong Chartered Governance Institute, The Chartered Governance Institute, the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants.</p>\n<p>Yang Dongyan, appointed Joint Company Secretary on 6 February 2026, will remain in her position and continue to serve as Innogen Pharmaceutical’s legal director.</p>\n<p>The Stock Exchange of Hong Kong granted a new waiver allowing Yang to continue serving as Joint Company Secretary without meeting the full experience requirements under Listing Rules 3.28 and 8.17. The waiver is valid until 5 February 2029, provided Yang is assisted by Mak and no material Listing Rules breaches occur. Before the waiver expires, Innogen Pharmaceutical must demonstrate that Yang has gained sufficient experience to discharge company-secretary duties independently.</p>\n<p>The board expressed appreciation for Sze’s contributions and welcomed Mak to her new roles.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1180017707","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180017707","pubTimestamp":1774268588,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"英诺药业修订公司秘书阵容，获港交所上市规则继续豁免","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her roles as Joint Company Secretary, Hong Kong Agent for Service of Process and Authorised Representative due to personal career plans.\nIndustry veteran Mak Po Man Cherie, currently Vice President of SWCS Corporate Services Group (Hong Kong) Limited, will assume the three vacated positions on the same date. Mak brings more than 20 years of audit, accounting, corporate finance, compliance and corporate secretarial experience, and holds professional memberships with The Hong Kong Chartered Governance Institute, The Chartered Governance Institute, the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants.\nYang Dongyan, appointed Joint Company Secretary on 6 February 2026, will remain in her position and continue to serve as Innogen Pharmaceutical’s legal director.\nThe Stock Exchange of Hong Kong granted a new waiver allowing Yang to continue serving as Joint Company Secretary without meeting the full experience requirements under Listing Rules 3.28 and 8.17. The waiver is valid until 5 February 2029, provided Yang is assisted by Mak and no material Listing Rules breaches occur. Before the waiver expires, Innogen Pharmaceutical must demonstrate that Yang has gained sufficient experience to discharge company-secretary duties independently.\nThe board expressed appreciation for Sze’s contributions and welcomed Mak to her new roles.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180017707","isCrawlerRequest":true}